ALK-Abelló A/S AKBLF Stock
ALK-Abelló A/S Price Chart
ALK-Abelló A/S AKBLF Financial and Trading Overview
| ALK-Abelló A/S stock price | 22.35 USD |
| Previous Close | 12.06 USD |
| Open | 12.06 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 12.06 - 12.06 USD |
| 52 Week Range | 10.5 - 21.43 USD |
| Volume | 164 USD |
| Avg. Volume | 8 USD |
| Market Cap | 2.81B USD |
| Beta (5Y Monthly) | 0.381992 |
| PE Ratio (TTM) | 54.818184 |
| EPS (TTM) | 0.56 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | March 16, 2017 |
| 1y Target Est | N/A |
AKBLF Valuation Measures
| Enterprise Value | 3.12B USD |
| Trailing P/E | 54.818184 |
| Forward P/E | 7.8823533 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 0.61233014 |
| Price/Book (mrq) | 0.6477603 |
| Enterprise Value/Revenue | 0.679 |
| Enterprise Value/EBITDA | 4.595 |
Trading Information
ALK-Abelló A/S Stock Price History
| Beta (5Y Monthly) | 0.381992 |
| 52-Week Change | -36.35% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 21.43 USD |
| 52 Week Low | 10.5 USD |
| 50-Day Moving Average | 12.34 USD |
| 200-Day Moving Average | 14.19 USD |
AKBLF Share Statistics
| Avg. Volume (3 month) | 8 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 200.74M |
| Float | 131.38M |
| Short Ratio | N/A |
| % Held by Insiders | 0% |
| % Held by Institutions | 61.08% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 20:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 7.29% |
| Operating Margin (ttm) | 11.19% |
| Gross Margin | 62.78% |
| EBITDA Margin | 14.77% |
Management Effectiveness
| Return on Assets (ttm) | 5.21% |
| Return on Equity (ttm) | 8.61% |
Income Statement
| Revenue (ttm) | 4.59B USD |
| Revenue Per Share (ttm) | 20.82 USD |
| Quarterly Revenue Growth (yoy) | 6.80% |
| Gross Profit (ttm) | 2.82B USD |
| EBITDA | 678M USD |
| Net Income Avi to Common (ttm) | 335M USD |
| Diluted EPS (ttm) | 0.22 |
| Quarterly Earnings Growth (yoy) | 0% |
Balance Sheet
| Total Cash (mrq) | 191M USD |
| Total Cash Per Share (mrq) | 0.86 USD |
| Total Debt (mrq) | 639M USD |
| Total Debt/Equity (mrq) | 15.52 USD |
| Current Ratio (mrq) | 2.014 |
| Book Value Per Share (mrq) | 18.618 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 479M USD |
| Levered Free Cash Flow (ttm) | 45.38M USD |
Profile of ALK-Abelló A/S
| Country | United States |
| State | N/A |
| City | Horsholm |
| Address | Boge Alle 6-8 |
| ZIP | 2970 |
| Phone | 45 45 74 75 76 |
| Website | https://www.alk.net |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 2712 |
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. It product portfolio include GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers much earlier in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intramuscular injection of adrenaline for the treatment of acute life-threatening allergic reactions including Anaphylaxis. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
Q&A For ALK-Abelló A/S Stock
What is a current AKBLF stock price?
ALK-Abelló A/S AKBLF stock price today per share is 22.35 USD.
How to purchase ALK-Abelló A/S stock?
You can buy AKBLF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ALK-Abelló A/S?
The stock symbol or ticker of ALK-Abelló A/S is AKBLF.
Which industry does the ALK-Abelló A/S company belong to?
The ALK-Abelló A/S industry is Biotechnology.
How many shares does ALK-Abelló A/S have in circulation?
The max supply of ALK-Abelló A/S shares is 245.47M.
What is ALK-Abelló A/S Price to Earnings Ratio (PE Ratio)?
ALK-Abelló A/S PE Ratio is 39.91071300 now.
What was ALK-Abelló A/S earnings per share over the trailing 12 months (TTM)?
ALK-Abelló A/S EPS is 0.56 USD over the trailing 12 months.
Which sector does the ALK-Abelló A/S company belong to?
The ALK-Abelló A/S sector is Healthcare.